Q2 FY2026 EarningsQ2 FY26 results missed GAAP EPS consensus significantly, reporting -$1.88 vs. -$0.40 expected, primarily due to a non-cash $205.6M fair value adjustment on warrant liabilities. Revenue remains at zero as expected for this clinical-stage biotech. Operating loss of $52.4M was slightly higher than the ~$47.1M EBIT consensus due to intensified commercial preparedness activities. Cash reserves of $433.3M provide a runway into 2028, supporting the ongoing Phase 3 TRD program and rolling NDA submission.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Compass Pathways(CMPS) the EBIT is -52.37 M (-21.99%), Miss estimate;the EPS is -1.88 (-358.5%), Miss estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
Revenue
TBA--
0.00B--
----
EBITMiss expectations
-0.05B21.99%
-0.05B9.62%
-0.01B12.37%
EPSMiss expectations
-1.88358.54%
-0.39713.14%
-1.4829361.68%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf